Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 1541-1549, April 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buhler, D. R.
Right arrow Articles by Jerina, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buhler, D. R.
Right arrow Articles by Jerina, D. M.

Effect of a 6-Fluoro Substituent on the Metabolism and Biological Activity of Benzo(a)pyrene

Donald R. Buhler1, Figen Ünlü2, Dhiren R. Thakker, Thomas J. Slaga, Allan H. Conney, Alexander W. Wood, Richard L. Chang, Wayne Levin and Donald M. Jerina3

Laboratory of Bioorganic Chemistry, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20205 [D. R. B., F. U., D. R. T., D. M. J.]; Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37803 [T. J. S.]; and Department of Biochemistry and Drug Metabolism, Hoffmann-La Roche Inc., Nutley, New Jersey 07110 [A. H. C., A. W. W., R. L. C., W. L.]

Cytochrome P-450-catalyzed epoxidation of (-)-(7R,8R)-dihydroxy-7,8-dihydrobenzo(a)pyrene to (+)-(7R,8S)-dihydroxy-(9S,10R)-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene is now well recognized as the primary pathway by which benzo(a)pyrene is converted to an ultimate carcinogen. The present metabolism studies of 6-fluorobenzo(a)pyrene indicate (a) that the 6-fluoro substituent does not dramatically block the formation of quinones involving position 6 and (b) that substantially more (~2-fold) of the 7,8-dihydrodiol is formed from 6-fluorobenzo(a)pyrene than is formed from benzo(a)pyrene. As is the case for benzo(a)pyrene, the 6-fluoro-7,8-dihydrodiol was found to be of high optical purity and has (7R,8R)absolute configuration. Electrostatic repulsion appears to cause the fluorinated 4,5- as well as 7,8-dihydrodiols to prefer the pseudodiaxial rather than the pseudodiequatorial conformation observed for these dihydrodiols when formed from benzo(a)pyrene. Comparision of the tumor-initiating activities of benzo(a)pyrene and 6-fluorobenzo(a)pyrene on the skin of female Sencar mice indicates that the fluorinated hydrocarbon is far less active in the initiation of tumors. In addition, the metabolites of the fluorinated 7,8-dihydrodiol do not display strong mutagenic activity toward Chinese hamster V79 cells. Altered conformation of the fluorinated 7,8-dihydrodiol and the resultant 7,8-diol-9,10-epoxide diastereomer in which the benzylic 7-hydroxyl group and the epoxide oxygen are trans provides a plausible explanation for the weak tumorigenicity of 6-fluorobenzo(a)pyrene on mouse skin, since all benzo-ring dihydrodiols and diol-epoxides in which the hydroxyl groups prefer the pseudodiaxial conformation are weak or inactive as carcinogens. In formulating the bay-region theory, we had pointed out that perifluorine substituents such as at position 6 in benzo(a)pyrene have a marked inhibitory effect on the tumorigenicity of the hydrocarbon. The present results provide a basis for this "perieffect."

1 Recipient of salary support from the Environmental Health Sciences Center, Oregon State University, Corvalis, Oreg., for a 1-year sabbatical leave during the academic year 1978–1979 during which time most of the present study was completed.

2 Present address: Turkish Atomic Energy Commission, Ankara, Turkey.

3 To whom requests for reprints should be addressed.

Received 6/11/82. Accepted 1/ 4/83.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.